During the study follow-up period, 74. The baseline use of all examined products, which included nonsteroidal anti-inflammatory drugs, corticosteroids, 5-aminosalicylic acid, oral immunosuppressants, and targeted therapies, was higher in the infliximab-naïve cohort when compared with switchers. 4%) and patients in the infliximab-naïve group most often switched to tumor necrosis factor inhibitor (TNF) biologics (10